Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 15/20 | 0.49 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.41 |
| ▸ | CCKBR | P32239 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14497681 | 1.00 | FOLH1 (0.49) | FOLH1FPR2NAALAD2CCKBR | |
| SCHEMBL14497770 | 0.97 | FOLH1 (0.46) | FOLH1FPR2NAALAD2CCKBR | |
| SCHEMBL4556926 | 0.92 | FOLH1 (0.50) | FOLH1FPR2NAALAD2CCKBR | |
| SCHEMBL4464533 | 0.91 | FOLH1 (0.49) | FOLH1NAALAD2CCKBR | |
| SCHEMBL4465270 | 0.91 | FOLH1 (0.49) | FOLH1FPR2NAALAD2CCKBR | |
| SCHEMBL14497677 | 0.91 | FOLH1 (0.49) | FOLH1NAALAD2CCKBR | |
| SCHEMBL13610863 | 0.91 | FOLH1 (0.49) | FOLH1FPR2NAALAD2CCKBR | |
| SCHEMBL14497683 | 0.89 | FOLH1 (0.47) | FOLH1FPR2NAALAD2CCKBR | |
| SCHEMBL13610257 | 0.88 | FOLH1 (0.52) | FOLH1FPR2NAALAD2CCKBR | |
| SCHEMBL14497773 | 0.88 | FOLH1 (0.46) | FOLH1FPR2NAALAD2CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534670-B1 | ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS | CANCER REC TECH LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| US-7235585-B2 | Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |
| US-20060069154-A1 | Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-03-30 | — | — | US | disclosed |
| EP-1534670-A1 | ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS | Cancer Research Technology Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004020400-A1 | ENZYME ACTIVATED SELF-IMMOLATIVE N-SUBSTITUTED NITROGEN MUSTARD PRODRUGS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069154-A1 | Enzyme activated self-immolative n-substituted nitrogen mustard prodrugs | CNDP2, PNP, APRT | FOLH1 267/4885FPR2 1930/4885NAALAD2 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.